Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SUTRO BIOPHARMA, INC.
Report date May 01, 2025 · Filed May 05, 2025
Section 16 reporting ended · disclosed 2025-05-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 119,744 |
Ending reported balance
After 2025-05-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2025-05-01 · Exercise / conversion · Acquired 9,125 · Balance 104,558 Row 2 · 2025-05-01 · Exercise / conversion · Acquired 9,740 · Balance 114,298 Row 3 · 2025-05-01 · Exercise / conversion · Acquired 13,140 · Balance 127,438 Row 4 · 2025-05-01 · Exercise / conversion · Acquired 5,844 · Balance 133,282 Row 5 · 2025-05-01 · Tax withholding · Disposed 13,538 · Balance 119,744 F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2026-03-04 | Direct | 0 |
Reported balance
After 2025-05-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-05-01 · Exercise / conversion · Disposed 9,125 · Balance 0 F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. F5: The reported transaction represents the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with her separation and transition from her position with the issuer. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2027-03-01 | Direct | 4,010 |
Reported balance
After 2025-05-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-05-01 · Exercise / conversion · Disposed 9,740 · Balance 4,010 F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5: The reported transaction represents the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with her separation and transition from her position with the issuer. F6: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2028-03-01 | Direct | 14,685 |
Reported balance
After 2025-05-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-05-01 · Exercise / conversion · Disposed 13,140 · Balance 14,685 F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5: The reported transaction represents the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with her separation and transition from her position with the issuer. F7: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2028-03-01 | Direct | 6,531 |
Reported balance
After 2025-05-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-05-01 · Exercise / conversion · Disposed 5,844 · Balance 6,531 F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5: The reported transaction represents the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with her separation and transition from her position with the issuer. F7: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. |
| Common StockSEC Table I · non-derivative | IndirectMichael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997 | 10,383 |
Reported balance
Holding disclosure · report date 2025-05-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 10,383 F2: These securities are held of record by Michael A. Fitzpatrick and Linda A. Fitzpatrick, Trustees of the Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2: These securities are held of record by Michael A. Fitzpatrick and Linda A. Fitzpatrick, Trustees of the Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997.
F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F4: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date.
F5: The reported transaction represents the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with her separation and transition from her position with the issuer.
F6: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date.
F7: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2022 Filed Mar 7, 2022 19:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 36,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016858 · doc4.xml · derivative · entry 5 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,500 Underlying: Common Stock · 36,500 shares Expires 2026-03-04 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 19:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 42,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001209191-22-016858 · doc4.xml · derivative · entry 4 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2032-03-03 F4 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on April 4, 2022, with 100% of the total shares vested and exercisable on March 4, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 20:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006131 · doc4.xml · derivative · entry 4 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 8,250 shares Expires 2025-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 20:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,380 | $10.39 | $35,118.20 |
DisclosureSEC source: 0001209191-22-006131 · doc4.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,546 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 20:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006131 · doc4.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 18:55 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 7,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057977 · doc4.xml · derivative · entry 4 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,576 shares Expires 2021-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 18:55 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,619 | $19.23 | $50,363.37 |
DisclosureSEC source: 0001209191-21-057977 · doc4.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,676 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 18:55 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 7,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057977 · doc4.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 17:18 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018619 · doc4.xml · derivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2025-03-05 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 17:18 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $21.11 | $0.00 |
DisclosureSEC source: 0001209191-21-018619 · doc4.xml · derivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-03-04 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on April 5, 2021, with 100% of the total shares vested and exercisable on March 5, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 17:54 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006556 · doc4.xml · derivative · entry 4 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,750 Underlying: Common Stock · 8,250 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 17:54 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,147 | $22.15 | $69,706.05 |
DisclosureSEC source: 0001209191-21-006556 · doc4.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,719 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 17:54 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006556 · doc4.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 17:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionStock Option (right to buy) · Derivative | 1,652 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001209191-21-004387 · doc4.xml · derivative · entry 3 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,652 shares Expires 2021-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 17:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 1,652 | $4.36 | $7,202.72 |
DisclosureSEC source: 0001209191-21-004387 · doc4.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:54 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 7,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052245 · doc4.xml · derivative · entry 4 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,576 Underlying: Common Stock · 7,576 shares Expires 2021-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:54 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,619 | $10.30 | $26,975.70 |
DisclosureSEC source: 0001209191-20-052245 · doc4.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,964 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:54 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 7,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052245 · doc4.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2020 Filed May 14, 2020 17:26 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | PurchaseCommon Stock | 3,225 | $7.75 | $24,993.75 |
DisclosureSEC source: 0001209191-20-029243 · doc4.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,007 Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 17:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005808 · doc4.xml · derivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2024-01-29 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 17:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 66,250 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001209191-20-005808 · doc4.xml · derivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,250 Underlying: Common Stock · 66,250 shares Expires 2030-01-29 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 29, 2020, with 100% of the total shares vested and exercisable on January 29, 2024, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 7,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051118 · doc4.xml · derivative · entry 4 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,152 Underlying: Common Stock · 7,575 shares Expires 2021-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,619 | $9.74 | $25,509.06 |
DisclosureSEC source: 0001209191-19-051118 · doc4.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,782 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 7,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051118 · doc4.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2019 Filed Aug 29, 2019 18:46 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionStock Option (right to buy Common Stock) · Derivative | 826 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0001209191-19-047755 · doc4.xml · derivative · entry 3 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 826 shares Expires 2019-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 29, 2019 Filed Aug 29, 2019 18:46 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 826 | $5.09 | $4,204.34 |
DisclosureSEC source: 0001209191-19-047755 · doc4.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:08 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 30,000 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-19-006202 · doc4.xml · derivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 28, 2019, with 100% of the total shares vested and exercisable on January 29, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:13 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionSeries D Preferred Stock · Derivative | 48,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052833 · doc4.xml · derivative · entry 6 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997 Disclosed balance after: 0 Underlying: Common Stock · 1,968 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: These securities are held of record by Michael A. Fitzpatrick and Linda A. Fitzpatrick, Trustees of the Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:13 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionSeries C Preferred Stock · Derivative | 94,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052833 · doc4.xml · derivative · entry 5 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997 Disclosed balance after: 0 Underlying: Common Stock · 3,501 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: These securities are held of record by Michael A. Fitzpatrick and Linda A. Fitzpatrick, Trustees of the Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:13 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionSeries B Preferred Stock · Derivative | 85,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052833 · doc4.xml · derivative · entry 4 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997 Disclosed balance after: 0 Underlying: Common Stock · 4,914 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: These securities are held of record by Michael A. Fitzpatrick and Linda A. Fitzpatrick, Trustees of the Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:13 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionCommon Stock | 1,968 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052833 · doc4.xml · nonDerivative · entry 3 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997 Disclosed balance after: 10,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: These securities are held of record by Michael A. Fitzpatrick and Linda A. Fitzpatrick, Trustees of the Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:13 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionCommon Stock | 3,501 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052833 · doc4.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997 Disclosed balance after: 8,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: These securities are held of record by Michael A. Fitzpatrick and Linda A. Fitzpatrick, Trustees of the Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:13 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionCommon Stock | 4,914 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052833 · doc4.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997 Disclosed balance after: 4,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: These securities are held of record by Michael A. Fitzpatrick and Linda A. Fitzpatrick, Trustees of the Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 17:51 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 22,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052480 · doc4.xml · derivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,727 Underlying: Common Stock · 22,727 shares Expires 2021-09-25 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 17:51 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 136,363 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052480 · doc4.xml · derivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,363 Underlying: Common Stock · 136,363 shares Expires 2028-09-25 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.